A research article published on 10 April 2020 found that including Benlysta (Belumimab) in the lupus treatment regimen early on may promote better outcomes.

The research project is the largest ever European nationwide cohort study aimed at investigating Benlysta’s effects on disease activity, damage progression and remission. The study included data from 466 people with active lupus receiving intravenous (IV) Benlysta at different medical centres across Italy. Scientists measured changes in participants’ disease activity, organ damage and remission status over a two-year period while receiving IV Benlysta treatment 

For the research article please click here.